Rash After CAR-T: Possible Causes
Rash after CAR-T therapy is most commonly a manifestation of cytokine release syndrome (CRS), but can also represent severe cutaneous eruptions, vascular cutaneous reactions, or direct immune-mediated toxicity—all requiring urgent evaluation given the associated mortality risk.
Primary Causes
1. Cytokine Release Syndrome (CRS)
CRS is the leading cause of rash following CAR-T infusion. The rash occurs as part of a systemic inflammatory response triggered by cytokine release from activated T cells and bystander immune cells 1.
Key characteristics:
- Timing: Peaks at 2-7 days post-infusion, but can occur up to 3 weeks later
- Associated symptoms: Fever (required for diagnosis), tachycardia, hypoxia, nausea, headache, hypotension
- Mechanism: Supraphysiologic cytokine release causing widespread inflammation
The rash in CRS is typically accompanied by fever and other systemic symptoms, distinguishing it from isolated dermatologic toxicity 1.
2. Severe Cutaneous Eruptions
Recent pharmacovigilance data reveals a 5-fold increased reporting of severe cutaneous eruptions with CAR-T therapy (ROR 5.18,95% CI 1.29-20.76) 2.
Critical features:
- Mortality: 50% of severe cutaneous eruption cases reported death as an outcome 2
- Presentation: Can mimic toxic epidermal necrolysis (TEN) with widespread erythematous macular eruption progressing to vesiculation and bullae 3
- Timing: Median onset 3 days post-infusion 2
- Distinguishing features: May have minimal mucosal involvement, unlike typical drug-induced TEN 3
3. Vascular Cutaneous Reactions
Vascular cutaneous events show a 3-fold increased reporting with CAR-T therapy (ROR 2.91,95% CI 1.51-5.60) 2.
Important considerations:
- Mortality: 25% of vascular cutaneous cases reported death 2
- Pathophysiology: Likely related to capillary leak and endothelial activation during cytokine storm
- Clinical presentation: Variable, may include petechiae, purpura, or other vascular phenomena
4. Direct Immune-Mediated Cutaneous Toxicity
Less common but documented reactions include immune-mediated dermatologic adverse events distinct from CRS 4.
Characteristics:
- May occur independently of systemic CRS symptoms
- Represents direct T-cell mediated inflammation
- Spectrum and mechanisms still being characterized
Diagnostic Approach
Immediate assessment priorities:
- Evaluate for CRS: Check for fever (mandatory), vital signs (hypotension, tachycardia), oxygen saturation
- Assess severity: Determine body surface area involvement, presence of blistering, mucosal involvement
- Rule out infection: Obtain cultures if superinfection suspected, particularly in neutropenic patients
- Timing correlation: Document days since CAR-T infusion (most reactions within first week)
Critical Management Pitfall
Do not dismiss rash as a minor toxicity. The mortality rates associated with severe cutaneous eruptions (50%) and vascular cutaneous reactions (25%) following CAR-T therapy demand immediate specialist evaluation 2.
Transfer to a CAR-T experienced center is strongly recommended for any patient developing rash post-CAR-T, as per ASCO guidelines 1. Patients should remain within 2 hours of their treating center for 4-8 weeks post-therapy and return immediately for any toxicities.
Additional Differential Considerations
While less common, also consider:
- Drug reactions: From concurrent medications (e.g., allopurinol, antibiotics)
- Infection: Viral exanthems in immunocompromised hosts
- Underlying malignancy: Cutaneous involvement of lymphoma
The temporal relationship to CAR-T infusion (median 3 days) and presence of systemic symptoms typically point toward CAR-T-related toxicity rather than alternative causes 2.